• Disease
  • Acne
  • Acne Papules
  • Geert F M J Cauwenbergh

    Prominent publications by Geert F M J Cauwenbergh

    KOL Index score: 7997

    Itraconazole is an orally active triazole antifungal which has been compared to griseofulvin in a number of double-blind trials. In dermatophytosis with a non-fixed treatment regimen for a maximum of 3 months, itraconazole 100 mg o.d. has produced a 100% mycological cure rate as compared with a 67% rate with griseofulvin 500 mg o.d. (p less than 0.01). Based on the pharmacokinetic profile, 100 mg itraconazole daily was then compared with 500 mg ultramicronized griseofulvin daily using a ...

    Also Ranks for: Tinea Pedis |  itraconazole griseofulvin |  3 months |  100 daily |  corporis cruris
    KOL Index score: 7408

    Itraconazole is an orally effective antifungal agent with a high affinity for tissues. The skin kinetics in human volunteers have been studied after administration of 100 and 200 mg of itraconazole daily. From day 7 onward, tissue levels in the beard region and on the back were consistently higher than the corresponding plasma levels. The levels in the palmar stratum corneum were lower than the corresponding plasma levels but persisted for 3 weeks after discontinuation of therapy. ...

    Also Ranks for: Skin Levels |  orally administered itraconazole |  griseofulvin humans |  pharmacokinetic profile |  discontinuation therapy
    KOL Index score: 7111

    Summary: A total of 137 patients with aspergillosis or aspergilloma has been treated with 50 to 400 mg itraconazole daily during 11 to 780 days.

    The global assessments »markedly improved« and »cured« were given to 60% of the treatments in invasive aspergillosis (n = 35) and reached 66% in chronic necrotising pulmonary aspergillosis (n = 44). These response rates are sufficiently high regarding the limited number of antifungal agents useful in aspergillosis. Sixty-two percent of the ...

    Also Ranks for: Treatment Aspergillosis |  abpa patients |  antifungal agents |  itraconazole therapy |  response rates
    KOL Index score: 6590

    Nail-matrix kinetics were studied in 21 patients (19 with onychomycosis, two with tinea corporis) as soon as taking itraconazole (Sporanox) 100 mg daily for up to 7 months. Itraconazole was detected in the distal nail as soon as 1 month after the start of therapy (42 ng/g in fingernails and 16 ng/g in toenails). During the course of treatment, this concentration rose and reached a mean of 160 ng/g in fingernail clippings and 197 ng/g in toenail clippings. Moreover, in fingernails of 12 ...

    Also Ranks for: Nail Matrix |  21 patients |  tinea corporis |  humans itraconazole |  ketoconazole male
    KOL Index score: 6516

    BACKGROUND: Seborrheic dermatitis is considered to be a Malassezia-driven disease. Little objective information is available so far from biometrological quantitative assessments of this skin condition. Pramiconazole is a novel triazole with potent in vitro antifungal activity, especially against Malassezia spp.

    OBJECTIVE: To study the sequential effects of pramiconazole on Malassezia, inflammation and epidermal changes.

    METHOD: This study was performed in 2 groups of subjects suffering ...

    Also Ranks for: Seborrheic Dermatitis |  malassezia spp |  skin condition |  antifungal agents |  administration oral
    KOL Index score: 6403

    Several reports have demonstrated the efficacy of topical ketoconazole in dermatologic conditions that are not exclusively related to fungi. Some basic pharmacologic studies have indicated effects of ketoconazole on cholesterol production in keratinocytes, on the 5-lipoxygenase enzyme, and on the metabolism of all-trans-retinoic acid in the skin. These observations have led to the hypothesis that topically applied ketoconazole may possess antiinflammatory properties. This hypothesis was ...

    Also Ranks for: Guinea Pigs |  antiinflammatory effects |  topical ketoconazole |  animal model |  combination therapy
    KOL Index score: 6379

    BACKGROUND: A problem in the treatment of onychomycosis is the lengthy duration of therapy. The pharmacokinetics of itraconazole suggest a potential for briefer treatment.

    OBJECTIVE: This study was designed to investigate itraconazole nail kinetics in 39 patients with onychomycosis in relation to their therapeutic outcome.

    METHODS: All patients received itraconazole for 3 months at a dose of 100 or 200 mg daily. Itraconazole levels of distal nail clippings were determined during a ...

    Also Ranks for: Itraconazole Levels |  treatment onychomycosis |  6 months |  nail bed |  antifungal agents
    KOL Index score: 6136

    Itraconazole (R 51211) is the prototype of a class of triazole antifungals characterized by a high lipophilicity. This property determines to a large extent the pharmacokinetics of itraconazole and differentiates it from the hydrophilic triazole antifungal fluconazole. The pharmacokinetics of itraconazole in man are characterized by a good oral absorption, an extensive tissue distribution with tissue concentrations many times higher than in plasma, a relatively long elimination half-life ...

    Also Ranks for: Pharmacokinetics Itraconazole |  oral absorption |  stratum corneum |  pharmacokinetic properties |  tissue distribution
    KOL Index score: 5838

    OBJECTIVES: To evaluate the age effect on both the mechanical properties and wrinkling of facial skin. This topic has not previously been addressed in the literature.

    DESIGN: A total of 180 white women aged 18 to 67 years participated in the study. Each of the 5 decades of age was represented by 30 subjects, with the exception of menopausal women aged 48 to 57 years who were allocated to two groups of 30 according to the use or non-use of hormone replacement therapy (HRT).

    SETTING: A ...

    Also Ranks for: Facial Skin |  mechanical properties |  menopausal women |  progressive increase |  30 subjects
    KOL Index score: 5558

    Itraconazole, an orally active broad-spectrum triazole antimycotic, has demonstrated anti-Cryptococcus activity in vitro and in animal models of cryptococcal meningitis. The drug has been used by a number of clinical groups for the treatment of cryptococcal meningitis, predominantly in AIDS patients. A problem that has been found with ketoconazole is the relatively low absorption of the drug in AIDS patients. This has resulted in ketoconazole plasma levels below the MIC90 (1-5 micrograms ...

    Also Ranks for: Cryptococcal Meningitis |  itraconazole ketoconazole |  cryptococcus neoformans |  aids patients |  oral therapy
    KOL Index score: 5420

    STUDY OBJECTIVE: To compare the pharmacokinetics of a single 100-mg oral dose of itraconazole administered as 10 ml of a 10-mg/ml itraconazole solution in hydroxypropyl-beta-cyclodextrin under fasting versus postprandial conditions.

    DESIGN: Open-label, two-way, randomized, crossover study.

    SETTING: Janssen Research Foundation, Belgium.

    PATIENTS: Twelve healthy volunteers.

    INTERVENTIONS: Blood samples were obtained for pharmacokinetic analyses immediately before dosing and at regular ...

    Also Ranks for: Food Pharmacokinetics |  blood samples |  new formulation itraconazole |  crossover study |  higher bioavailability
    KOL Index score: 5163

    BACKGROUND: The pathogenesis of androgenic alopecia is not fully understood. A microbial-driven inflammatory reaction abutting on the hair follicles might participate in the hair status anomaly.

    OBJECTIVE: The aim of our study was to determine if ketoconazole (KCZ) which is active against the scalp microflora and shows some intrinsic anti-inflammatory activity might improve alopecia.

    METHOD: The effect of 2% KCZ shampoo was compared to that of an unmedicated shampoo used in combination ...

    Also Ranks for: Androgenic Alopecia |  ketoconazole shampoo |  hair follicles |  inflammatory reaction |  malassezia spp
    KOL Index score: 5103

    BACKGROUND: During photoaging, the density of melanin chromatophores is heterogeneous in the epidermis.

    AIMS: To define the patterns of pheomelanin-enriched melanotic hypermelanosis of the face in phototype II subjects and to assess the effect of depigmenting agents. Azelaic acid and glycolic acid were tested as well as a soy extract, reported to reduce pigmentation through interaction with the protease-activated receptor 2 (PAR-2) of keratinocytes.

    METHOD: Evaluations were made by image ...

    Also Ranks for: Depigmenting Agents |  image analysis |  azelaic acid |  skin pigmentation |  pigmentary disorders


    Geert F M J Cauwenbergh: Influence Statistics

    Sample of concepts for which Geert F M J Cauwenbergh is among the top experts in the world.
    Concept World rank
    inside keratinocytes #1
    pharmacokinetics aids patients #1
    amorphous lipidlike droplets #1
    itraconazole treat #1
    keratinocytes amorphous material #1
    itraconazole trial #1
    systemically active agents #1
    ketoconazole scalp #1
    moment complete suppression #1
    skin kinetics #1
    treatment phaeohyphomycosis #1
    itraconazol behandlung #1
    skin kinetics antifungals #1
    versicolor phaeohyphomycosis #1
    normal keratinous content #1
    tetrahydroimidazol #1
    aids patients tibo #1
    itraconazole orally #1
    essential nutritive factor #1
    dose steroids antibiotics #1
    oral antifungal addition #1
    keratinocyte degradation #1
    completely opposite sides #1
    ketoconazole drug #1
    skin dermatophytoses #1
    itraconazole therapeutic #1
    100 itraconazole #1
    phaeohyphomycosis pityriasis versicolor #1
    predisposing factors neonates #1
    ultraviolet light block #1
    itraconazole daily #1
    ketoconazole skin #1
    oral topical ketoconazole #1
    therapeutic options phaeohyphomycosis #1
    data skin kinetics #1
    oral bioavailability tibo #1
    children oral candidosis #1
    lipidified state #1
    opportunistic infections itraconazole #1
    topical antifungals griseofulvin #1
    neonates oral candidosis #1
    fungal infection availability #1
    oral candidosis neonates #1
    pharmacokinetics 82913 #1
    bacterial infections moment #1

    Key People For Acne Papules

    Top KOLs in the world
    William James Cunliffe
    acne vulgaris benzoyl peroxide sebum excretion rate
    Brigitte DRENO
    metastatic melanoma consultancy funding acne vulgaris
    Florence Poli
    hidradenitis suppurativa acne vulgaris chemical peels
    Martine Chivot
    zinc gluconate acne vulgaris androgen receptor
    Géerald E Piérard
    stratum corneum toxic epidermal necrolysis seborrheic dermatitis
    Christos Constantin Zouboulis
    hidradenitis suppurativa human sebocytes sebaceous glands
    Select a search phrase   acne papules

    Geert F M J Cauwenbergh:Expert Impact

    Concepts for whichGeert F M J Cauwenberghhas direct influence:Acne papules,  Pityriasis versicolor,  Oral candidosis,  Skin kinetics,  Itraconazole ketoconazole,  Topical ketoconazole,  Oral administration,  Facial skin.

    Geert F M J Cauwenbergh:KOL impact

    Concepts related to the work of other authors for whichfor which Geert F M J Cauwenbergh has influence:Antifungal agents,  Fungal infections,  Tinea capitis,  Pityriasis versicolor,  Itraconazole treatment,  Seborrheic dermatitis,  Stratum corneum.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Barrier Therapeutics Inc., 600 College Road East, Suite 3200, Princeton, NJ 08540, U.S.A. | Maastricht University, Department of Molecular Cell Biology, Maastricht, The Netherlands 4Phases 123, Princeton, NJ, USA | Department of Dermatopathology, Uni